Changes in the process of alternative RNA splicing results in soluble B and T lymphocyte attenuator with biological and clinical implications in critical illness

Abstract

BackgroundCritically ill patients with sepsis and acute respiratory distress syndrome have severely altered physiology and immune system modifications. RNA splicing is a basic molecular mechanism influenced by physiologic alterations. Immune checkpoint inhibitors, such as B and T Lymphocyte Attenuator (BTLA) have previously been shown to influence outcomes in critical illness. We hypothesize altered physiology in critical illness results in alternative RNA splicing of the immune checkpoint protein, BTLA, resulting in a soluble form with biologic and clinical significance.MethodsSamples were collected from critically ill humans and mice. Levels soluble BTLA (sBTLA) were measured. Ex vivo experiments assessing for cellular proliferation and cytokine production were done using splenocytes from critically ill mice cultured with sBTLA. Deep RNA sequencing was done to look for alternative splicing of BTLA. sBTLA levels were fitted to models to predict sepsis diagnosis.ResultssBTLA is increased in the blood of critically ill humans and mice and can predict a sepsis diagnosis on hospital day 0 in humans. Alternative RNA splicing results in a premature stop codon that results in the soluble form. sBTLA has a clinically relevant impact as splenocytes from mice with critical illness cultured with soluble BTLA have increased cellular proliferation.ConclusionsBTLA is produced as a result of alternative RNA splicing. This isoform of BTLA has biological significance through changes in cellular proliferation and can predict the diagnosis of sepsis.

Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma

“…The soluble forms of CD27 can contribute to the activation of T cells and B cells 37,38 . In addition, previous studies have shown an increase in sBTLA levels in the blood of critically ill humans and mice 39 , and malignant melanoma cells express MHC-II, blinded sLAG-3 to up-regulate anti-apoptotic pathways 40 . Notably, at week 2 of sorafenib treatment, sCD27 levels were decreased from baseline ( Fig.…”

Landscape of transcript isoforms in single T cells infiltrating in non-small cell lung cancer

“…The splicing of BTLA-202 leads to loss of the transmembrane helix domain, resulting in a soluble BTLA product compared with the canonical isoform. This soluble isoform was confirmed and found to increase in the early stages of sepsis(51, 52) and was able to enhance antitumor activity in a melanoma pulmonary metastasis model in combination of HSP70 vaccine(53). Thus, the enrichment of T BTLA 202 cells in CD8+ exhausted T cells may suggest a new mechanism for the induction of immunosuppressive tumor microenvironment.…”

Immune Checkpoint Molecules—Inherited Variations as Markers for Cancer Risk

“…The BTLA gene structure is shown in Figure 4 . BTLA has three splicing variants: full length BTLA has five exons and possess a Ig-C like domain; the BTLA isoform with 70% extracellular domain missing due to a skipped exon 3 and soluble BTLA which lacks a fragment of exon 4 due to alternative 3’ splice site caused by a premature stop codon ( 209 ).…”